Segments - Immunohistochemistry Market by Products (Antibodies [Primary Antibodies and Secondary Antibodies], Equipment [Slide Staining Systems, Tissue Microarrays, Tissue Processing Systems, Slide Scanners, and Others], Reagents [Histological Stains, Blocking sera & Reagents, Chromogenic Substrates, Fixation Reagents, Stabilizers, Organic Solvents, Proteolytic Enzymes, and Diluents], and Kits), Applications (Diagnostics [Cancer, Infectious Diseases, Cardiovascular Diseases, Autoimmune Diseases, Diabetes Mellitus, and Nephrological Diseases] and Drug Testing), End-users (Hospitals & Diagnostic Laboratories, Research Institutes, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 - 2031
The global immunohistochemistry market size was valued at USD 2.98 Billion in 2022 and is projected to reach USD 5.67 Billion by 2031, expanding at a CAGR of 7.4% during the forecast period 2023 - 2031. The growth of the market is attributed to technologically advanced immunohistochemistry solutions, increasing drug discovery and development activities, and rising prevalence of chronic diseases.
Immunohistochemistry (IHC), a critical application of monoclonal and polyclonal antibodies, aids in the study of an antigen's tissue distribution. It is utilized to find enzymes, tumor suppressor genes, antigens, and the proliferation of tumor cells. IHC is a technique that uses the concept of antibodies attaching selectively to antigens in biological tissues to detect antigens or haptens in cells of a tissue segment.
IHC has become an important diagnostic tool for a variety of chronic disorders including cancer, infectious disorders, and cardiovascular diseases (CVDs). As a result of the increase in the incidence of these chronic diseases, the need for IHC techniques has increased. IHC is also an important technique in the development of biomarkers, hence the market has been growing in line with the rising need for biomarkers.
Various immunohistochemistry equipment, such as slide staining systems, tissue microarrays (TMA), tissue processing systems, slide scanners, and other equipment, are utilized in the diagnostic and drug testing procedure.
The report on the global immunohistochemistry market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Immunohistochemistry Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Products (Antibodies [Primary Antibodies, Secondary Antibodies], Equipment [Slide Staining Systems, Tissue Microarrays, Tissue Processing Systems, Slide Scanners, and Others], Reagents [Histological Stains, Blocking Sera & Reagents, Chromogenic Substrates, Fixation Reagents, Stabilizers, Organic Solvents, Proteolytic Enzymes, and Diluents], and Kits), Applications (Diagnostics [Cancer, Infectious Diseases, Cardiovascular Diseases, Autoimmune Diseases, Diabetes Mellitus, and Nephrological Diseases] and Drug Testing), and End-users (Hospitals & Diagnostic Laboratories, Research Institutes, and Others) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Abcam plc; Agilent Technologies; Bio SB; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Danaher Corporation; F. Hoffmann-La Roche AG; Merck KGaA; PerkinElmer, Inc.; and Thermo Fisher Scientific, Inc. |
Based on products, the global immunohistochemistry market is segmented into antibodies, equipment, reagents, and kits. The antibodies segment is further divided into primary antibodies, secondary antibodies. The equipment segment consists of slide staining systems, tissue microarrays, tissue processing systems, slide scanners, and others.
Meanwhile, the reagents segment includes histological stains, blocking sera & reagents, chromogenic substrates, fixation reagents, stabilizers, organic solvents, proteolytic enzymes, and diluents. The antibodies segment is expected to account for a key share of the market in the coming years owing to the continuous usage in IHC procedures for disease diagnosis and drug testing.
Therapeutic monoclonal antibodies and antibody-related products such as antibody fragments, Fc-fusion proteins, and antibody-drug conjugates are major product categories to become the market's leading product class. The primary antibodies segment dominated the immunohistochemistry market as these products are mainly used in the diagnosis of chronic diseases at a large extent.
The kits segment, on the other hand, is anticipated to grow significantly during the forecast period due to their compact nature and convenience. IHC kits are widely used in research laboratories and academic institutions that need limited quantities of these items for conducting research, as opposed to other end-use settings that require large quantities.
On the basis of applications, the market is bifurcated into drug testing and diagnostics. The diagnostic segment is further segmented into cancer, infectious diseases, cardiovascular diseases, autoimmune diseases, diabetes mellitus, and nephrological diseases. The diagnostics segment is expected to expand significantly during the forecast period due to its wide prevalence of chronic diseases.
Moreover, growing number of R&D activities by key pharmaceutical companies and wide adoption of advanced technology for the discovery and production of novel drugs are expected to boost demand for IHC solutions and support the segmental growth.
Based on end-users, the global immunohistochemistry market is segmented into research institutes, hospitals & diagnostic laboratories, and others. The Hospitals and diagnostic laboratories segment is projected to constitute a key market share during the forecast period owing to increase in the demand for disease diagnosis, impacted by the rise in the incidence of chronic diseases.
Furthermore, the advancement in technology such as automated sample preparation and digital pathology have added significant value of the segment. Additionally, the growing number of hospitals and clinical research laboratories are key drivers boosting the demand for diagnostics, propelling the segment growth.
Meanwhile, the research institutes segment is anticipated to grow significantly during the forecast period due to the increasing adoption of IHC solutions in research institutes for drug discovery and development activities. The other end-users segment includes contract research organizations (CROs) and forensic laboratories. The growing trend of pharmaceutical and biotech companies involved in the outsourcing drug development activities is expected to boost the CROs segment's growth.
In terms of regions, the market is segmented into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to register a substantial growth rate in terms of revenue share during the forecast period. The regional growth market is attributed to well-established healthcare infrastructure, which has led to an increase in the adoption of IHC instruments in laboratories and diagnostic centers.
The favorable reimbursement framework in this region presents a key factor boosting the market penetration of automated immunohistochemistry instruments. The increasing incidence of cancer in the region is another factor for the market growth in the region.
The market in Asia Pacific, however, is expected to grow significantly during the forecast period due to rapid economic development in countries such as China, India, South Korea, and Singapore. Furthermore, the rapidly aging population and the high prevalence of chronic diseases are expected to be major drivers of the immunohistochemistry market in the region.
Some of the major players competing in the immunohistochemistry market are Thermo Fisher Scientific, Inc.; F. Hoffmann-La Roche Ltd.; Merck KGaA; Danaher Corporation; Perkinelmer, Inc.; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Bio SB; Agilent Technologies, Inc.; and Abcam plc.
To improve their market position and gain a significant market share, these major players are constantly focusing to implement organic growth strategies such as product creation and upgradation. For example, Danaher Corporation's subsidiary, Leica Biosystems launched an updated version of its BOND-III IHC and ISH stainer in March 2018 with an aim to offer ease-of-use of both the instrument hardware and software. Similarly, PerkinElmer announced the release of Vectra Polaris, an Automated Quantitative Pathology Imaging System, In January 2017, which was intended to help researchers gain a better understanding of cancer immunotherapy strategies.